Arcturus Therapeutics Holdings Inc. (ARCT) News
Filter ARCT News Items
ARCT News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ARCT News Highlights
- ARCT's 30 day story count now stands at 5.
- Over the past 13 days, the trend for ARCT's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- BODY, CSL and LE are the most mentioned tickers in articles about ARCT.
Latest ARCT News From Around the Web
Below are the latest news stories about ARCTURUS THERAPEUTICS HOLDINGS INC that investors may wish to consider to help them evaluate ARCT as an investment opportunity.
CSL and Arcturus Therapeutics’ ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine BoosterKING OF PRUSSIA, Pa. & SAN DIEGO, December 21, 2023--Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) and Arcturus Therapeutics (Nasdaq: ARCT) today announced the publication in Lancet Infectious Diseases of a Phase 3 study showing that a booster dose of ARCT-154, a novel, self-amplifying messenger RNA (sa-mRNA) vaccine, elicited a numerically higher immune response (meeting the non-inferiority criteria) against the original Wuhan-Hu-1 virus strain, and a superior immune response against O |
7 Undervalued Biotech Stocks That are Flying Under the Clinical RadarWith so many innovative firms skyrocketing this year, astute investors seeking compelling discounts may want to turn their attention to undervalued biotech picks. |
3 Biotech Stocks With Promising Pipelines and Big Growth Potential in 2024These biotech stocks with promising pipelines are showing some major promise and growth potential for the new year. |
Is There An Opportunity With Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) 46% Undervaluation?Key Insights The projected fair value for Arcturus Therapeutics Holdings is US$47.95 based on 2 Stage Free Cash Flow to... |
12 Best Healthcare Stocks For the Long-TermIn this piece, we will take a look at the 12 best healthcare stocks for the long term. If you want to skip our overview of the healthcare industry, then you can take a look at 5 Best Healthcare Stocks For the Long-Term. The healthcare industry is one of the biggest industries in the world. […] |
Arcturus Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceSAN DIEGO, December 04, 2023--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that Joseph Payne, President & Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, on Tuesday, January 9, 2024, at 3:00 p.m. |
The Zacks Analyst Blog Highlights Avidity, Bristol Myers Squibb, Vertex, Arcturus and BioVieAvidity, Bristol Myers Squibb, Vertex, Arcturus and BioVie are included in this Analyst Blog. |
Biotech Stock Roundup: RNA Up on BMY Deal Expansion, BIVI Down on Setback & MoreRegulatory and pipeline updates from Avidity Biosciences, Inc. (RNA) and BioVie (BIVI) are in the spotlight this week. |
Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the first Self-Amplifying mRNA vaccine approved for COVID in adultsGlobal biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) and Arcturus Therapeutics today announced that Japan's Ministry of Health, Labor and Welfare (MHLW) granted approval for ARCT-154, a self-amplifying mRNA (sa-mRNA) COVID-19 vaccine for initial vaccination and booster for adults 18 years and older. |
Arcturus' (ARCT) CF Drug Gets FDA's Orphan Status, Stock UpArcturus (ARCT) rises 8% as the FDA grants Orphan Drug Designation for its product candidate, ARCT-032, for the treatment of cystic fibrosis. |